Fusion Antibodies PLC Block admission six monthly return (7158O)
04 Oktober 2023 - 3:45PM
UK Regulatory
TIDMFAB
RNS Number : 7158O
Fusion Antibodies PLC
04 October 2023
Fusion Antibodies plc
("Fusion" or the "Company")
Block admission six monthly return
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, announces the following
information in connection with its block admission pursuant to AIM
Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company: Fusion Antibodies plc
Name of scheme: Historic options, EMI and Unapproved
Employee Share Option Scheme,
as announced on 27 September
2021
--------------------------------------
Period of return: From 2 April 2023 to 1 October
2023
--------------------------------------
Number and class of securities 752,083 ordinary shares of 4
not issued under the scheme pence each in the Company ("Ordinary
at the beginning of the period: Shares")
--------------------------------------
Number of securities issued Nil
under the scheme during the
period:
--------------------------------------
Number of options under the Options over 458,333 Ordinary
scheme that have lapsed during Shares
the period:
--------------------------------------
Balance under the scheme of 293,750 Ordinary Shares
securities not yet issued at
the end of the period:
--------------------------------------
Number and class of securities 917,083 Ordinary Shares on 27
originally admitted and the September 2021
date of admission:
--------------------------------------
Contact name and telephone number: Stephen Smyth, Interim CFO via
Walbrook PR
+44 (0)20 7933 8780
--------------------------------------
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer Via Walbrook PR
Stephen Smyth, Interim Chief Financial
Officer
Allenby Capital Limited Tel: +44 (0)20 3328
5656
James Reeve/Vivek Bhardwaj (Corporate
Finance)
Tony Quirke/Joscelin Pinnington (Sales
and Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741
001
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx (TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotech companies get to
the clinic faster, with the optimal drug candidate and ultimately
speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at
$135.4 billion in 2018 and is forecast to surpass $212.6 billion in
2022, an increase at a CAGR of 12.0 per cent. for the period 2018
to 2022. In 2017, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $63.2 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRNKQBQNBDDNKK
(END) Dow Jones Newswires
October 04, 2023 09:45 ET (13:45 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
